74512 Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 

Limited disclosure of business 

proprietary information (BPI) under an 

administrative protective order (APO) 

and BPI service list.—Pursuant to 

§ 207.7(a) of the Commission’s rules, the 

Secretary will make BPI gathered in 

these investigations available to 

authorized applicants representing 

interested parties (as defined in 19 

U.S.C. 1677(9)) who are parties to the 

investigations under the APO issued in 

the investigations, provided that the 

application is made not later than seven 

days after the publication of this notice 

in the Federal Register. A separate 

service list will be maintained by the 

Secretary for those parties authorized to 

receive BPI under the APO. 

Conference.—The Office of 

Investigations will hold a staff 

conference in connection with the 

preliminary phase of these 

investigations beginning at 9:30 a.m. on 

Wednesday, November 15, 2023. 

Requests to appear at the conference 

should be emailed to 

preliminaryconferences@usitc.gov (DO 

NOT FILE ON EDIS) on or before 

November 13, 2023. Please provide an 

email address for each conference 

participant in the email. Information on 

conference procedures, format, and 

participation will be available on the 

Commission’s Public Calendar. A 

nonparty who has testimony that may 

aid the Commission’s deliberations may 

request permission to participate by 

submitting a short statement. 

Please note the Secretary’s Office will 

accept only electronic filings during this 

time. Filings must be made through the 

Commission’s Electronic Document 

Information System (EDIS, https://

edis.usitc.gov). No in-person paperbased filings or paper copies of any 

electronic filings will be accepted until 

further notice. 

Written submissions.—As provided in 

§§ 201.8 and 207.15 of the 

Commission’s rules, any person may 

submit to the Commission on or before 

5:15 p.m. on November 20, 2023, a 

written brief containing information and 

arguments pertinent to the subject 

matter of the investigations. Parties shall 

file written testimony and 

supplementary material in connection 

with their presentation at the conference 

no later than noon on November 14, 

2023. All written submissions must 

conform with the provisions of § 201.8 

of the Commission’s rules; any 

submissions that contain BPI must also 

conform with the requirements of 

§§ 201.6, 207.3, and 207.7 of the 

Commission’s rules. The Commission’s 

Handbook on Filing Procedures, 

available on the Commission’s website 

at https://www.usitc.gov/documents/ 

handbook_on_filing_procedures.pdf, 

elaborates upon the Commission’s 

procedures with respect to filings. 

In accordance with §§ 201.16(c) and 

207.3 of the rules, each document filed 

by a party to the investigations must be 

served on all other parties to the 

investigations (as identified by either 

the public or BPI service list), and a 

certificate of service must be timely 

filed. The Secretary will not accept a 

document for filing without a certificate 

of service. 

Certification.—Pursuant to § 207.3 of 

the Commission’s rules, any person 

submitting information to the 

Commission in connection with these 

investigations must certify that the 

information is accurate and complete to 

the best of the submitter’s knowledge. In 

making the certification, the submitter 

will acknowledge that any information 

that it submits to the Commission 

during these investigations may be 

disclosed to and used: (i) by the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of these or related investigations or 

reviews, or (b) in internal investigations, 

audits, reviews, and evaluations relating 

to the programs, personnel, and 

operations of the Commission including 

under 5 U.S.C. Appendix 3; or (ii) by 

U.S. government employees and 

contract personnel, solely for 

cybersecurity purposes. All contract 

personnel will sign appropriate 

nondisclosure agreements. 

Authority: These investigations are 

being conducted under authority of title 

VII of the Tariff Act of 1930; this notice 

is published pursuant to § 207.12 of the 

Commission’s rules. 

By order of the Commission. 

Issued: October 25, 2023. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2023–23947 Filed 10–30–23; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[USITC SE–23–052] 

Sunshine Act Meetings 

AGENCY HOLDING THE MEETING: United 

States International Trade Commission. 

TIME AND DATE: November 3, 2023 at 

11:00 a.m. 

PLACE: Room 101, 500 E Street SW, 

Washington, DC 20436, Telephone: 

(202) 205–2000. 

STATUS: Open to the public. 

MATTERS TO BE CONSIDERED: 

1. Agendas for future meetings: none. 

2. Minutes. 

3. Ratification List. 

4. Commission vote on Inv. No. 731– 

TA–472 (Fifth Review) (Silicon Metal 

from China). The Commission currently 

is scheduled to complete and file its 

determinations and views of the 

Commission on November 14, 2023. 

5. Outstanding action jackets: none. 

CONTACT PERSON FOR MORE INFORMATION: 

Sharon Bellamy, Supervisory Hearings 

and Information Officer, 202–205–2000. 

The Commission is holding the 

meeting under the Government in the 

Sunshine Act, 5 U.S.C. 552(b). In 

accordance with Commission policy, 

subject matter listed above, not disposed 

of at the scheduled meeting, may be 

carried over to the agenda of the 

following meeting. 

By order of the Commission. 

Issued: October 27, 2023. 

Sharon Bellamy, 

Supervisory Hearings and Information 

Officer. 

[FR Doc. 2023–24073 Filed 10–27–23; 11:15 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1051A] 

Proposed Adjustments to the 

Aggregate Production Quotas for 

Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2023 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: The Drug Enforcement 

Administration (DEA) proposes to 

adjust the 2023 aggregate production 

quotas for several controlled substances 

in schedules I and II of the Controlled 

Substances Act (CSA) and the 

assessment of annual needs for the list 

I chemical phenylpropanolamine. 

DATES: Interested persons may file 

written comments on this notice in 

accordance with 21 CFR 1303.13(c) and 

1315.13(d). Electronic comments must 

be submitted, and written comments 

must be postmarked, on or before 

November 30, 2023. Commenters should 

be aware that the electronic Federal 

Docket Management System will not 

accept comments after 11:59 p.m. 

Eastern Time on the last day of the 

comment period. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 74513 

1 28 CFR 0.100(b). 

2Established Aggregate Production Quotas for 

Schedule I and II Controlled Substances and 

Assessment of Annual Needs for the List I 

Chemicals Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2023, 87 FR 74168 

(December 2, 2022). 

3 21 CFR 1303.13(a) and 1315.13(a). 

4 DEA recently adopted revisions to its 

regulations for setting quotas, but that rule has not 

yet taken effect and does not affect this notice 

proposing some adjustments to the 2023 APQs. 

Management of Quotas for Controlled Substances 

and List I Chemicals, 88 FR 60117 (Aug. 31, 2023) 

(effective Nov. 29, 2023). 

Based on comments received in 

response to this notice, the 

Administrator may hold a public 

hearing on one or more issues raised. In 

the event the Administrator decides in 

her sole discretion to hold such a 

hearing, the Administrator will publish 

a notice of any such hearing in the 

Federal Register. After consideration of 

any comments or objections, or after a 

hearing, if one is held, the 

Administrator will publish in the 

Federal Register a final order 

establishing the 2023 adjusted aggregate 

production quotas for schedule I and II 

controlled substances, and an adjusted 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, as relevant. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–1051A’’ on all 

correspondence, including any 

attachments. DEA encourages that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to http:// 

www.regulations.gov and follow the 

online instructions at that site for 

submitting comments. Upon completion 

of your submission, you will receive a 

Comment Tracking Number for your 

comment. Please be aware that 

submitted comments are not 

instantaneously available for public 

view on Regulations.gov. If you have 

received a Comment Tracking Number, 

your comment has been successfully 

submitted and there is no need to 

resubmit the same comment. Paper 

comments that duplicate electronic 

submissions are not necessary and are 

discouraged. Should you wish to mail a 

paper comment in lieu of an electronic 

comment, it should be sent via regular 

or express mail to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

FOR FURTHER INFORMATION CONTACT: 

Scott A. Brinks, Regulatory Drafting and 

Policy Support Section, Diversion 

Control Division, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: 571–776–3882. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received in response to this docket are 

considered part of the public record. 

The Drug Enforcement Administration 

(DEA) will make comments available for 

public inspection online at http://

www.regulations.gov. Such information 

includes personal or business identifiers 

(such as name, address, state or Federal 

identifiers, etc.) voluntarily submitted 

by the commenter. Generally, all 

information voluntarily submitted by 

the commenter, unless clearly marked 

as Confidential Information in the 

method described below, will be 

publicly posted. Comments may be 

submitted anonymously. The Freedom 

of Information Act applies to all 

comments received. 

Commenters submitting comments 

which include personal identifying 

information (PII), confidential, or 

proprietary business information that 

the commenter does not want made 

publicly available should submit two 

copies of the comment. One copy must 

be marked ‘‘CONTAINS 

CONFIDENTIAL INFORMATION’’ and 

should clearly identify all PII or 

business information the commenter 

does not want to be made publicly 

available, including any supplemental 

materials. DEA will review this copy, 

including the claimed PII and 

confidential business information, in its 

consideration of comments. The second 

copy should be marked ‘‘TO BE 

PUBLICLY POSTED’’ and must have all 

claimed confidential PII and business 

information already redacted. DEA will 

post only the redacted comment on 

http://www.regulations.gov for public 

inspection. 

For easy reference, an electronic copy 

of this document is available at http:// 

www.regulations.gov. 

Legal Authority and Background 

Section 306 of the CSA (21 U.S.C. 

826) requires the Attorney General to 

establish aggregate production quotas 

(APQ) for each basic class of controlled 

substance listed in schedules I and II 

and for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. The Attorney 

General has delegated this function to 

the Administrator of DEA.1

DEA established the 2023 APQ for 

substances in schedules I and II and the 

assessment of annual needs (AAN) for 

the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine on December 2, 

2022.2 That order stipulated that, in 

accordance with 21 CFR 1303.13 and 

1315.13, all APQ and AAN are subject 

to adjustment. 

Analysis for Proposed Adjusted 2023 

Aggregate Production Quotas and 

Assessment of Annual Needs 

DEA proposes to adjust the 

established 2023 APQ for certain 

schedule I and II controlled substances 

and the AAN for certain list I chemicals 

to be manufactured in the United States 

(U.S.) in 2023 to provide for the 

estimated medical, scientific, research, 

and industrial needs of the U.S., for 

lawful export requirements, and for the 

establishment and maintenance of 

reserve stocks. These quotas do not 

include imports of controlled 

substances for use in industrial 

processes. 

Factors for Determining the Proposed 

Adjustments 

In determining the proposed 

adjustments, the Administrator has 

taken into account the factors in 21 CFR 

1303.13 (adjustment of APQ for 

controlled substances) and 21 CFR 

1315.13 (adjustment of the AAN for 

ephedrine, pseudoephedrine, and 

phenylpropanolamine). The 

Administrator is authorized to increase 

or reduce the APQ and the AAN at any 

time.3

DEA determined whether to propose 

an adjustment of the APQ for 2023 by 

considering the factors found at 21 CFR 

1303.13(b): 4

(1) Changes in the demand for that class, 

changes in the national rate of net disposal 

of the class, changes in the rate of net 

disposal of the class by registrants holding 

individual manufacturing quotas for that 

class, and changes in the extent of any 

diversion in the class; 

(2) Whether any increased demand for that 

class, the national and/or individual rates of 

net disposal of that class are temporary, short 

term, or long term; 

(3) Whether any increased demand for that 

class can be met through existing inventories, 

increased individual manufacturing quotas, 

or increased importation, without increasing 

the aggregate production quota, taking into 

account production delays and the 

probability that other individual 

manufacturing quotas may be suspended 

pursuant to Sec. 1303.24(b); 

(4) Whether any decreased demand for that 

class will result in excessive inventory 

accumulation by all persons registered to 

handle that class (including manufacturers, 

distributors, practitioners, importers, and 


lotter on DSK11XQN23PROD with NOTICES1
74514 Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 

5 74 FR 60294 (Nov. 20, 2009) and 75 FR 79407 

(Dec. 20, 2010). 

6 Id. 

7 21 U.S.C. 826(i)(1)(A). 

8 21 U.S.C. 826(i)(1)(A). 

9All functions vested in the Attorney General by 

the CSA have been delegated to the Administrator 

of DEA. 28 CFR 0.100(b); 21 U.S.C. 826(i)(1)(C). 

10 21 U.S.C. 826(i)(1)(B). 

11 87 FR 63091 (October 18, 2022). 

12 87 FR 74168. 

exporters), notwithstanding the possibility 

that individual manufacturing quotas may be 

suspended pursuant to Sec. 1303.24(b) or 

abandoned pursuant to Sec. 1303.27; 

(5) Other factors affecting medical, 

scientific, research, and industrial needs in 

the United States and lawful export 

requirements, as the Administrator finds 

relevant, including changes in the currently 

accepted medical use in treatment with the 

class or the substances which are 

manufactured from it, the economic and 

physical availability of raw materials for use 

in manufacturing and for inventory purposes, 

yield and stability problems, potential 

disruptions to production (including possible 

labor strikes), and recent unforeseen 

emergencies such as floods and fires. 

DEA also considered updated 

information obtained from 2022 yearend inventories, 2022 disposition data 

submitted by quota applicants, changes 

in estimates of the medical needs of the 

U.S., export requirements, and other 

information made available to DEA after 

the initial APQ and AAN had been 

established. Additional factors the 

Administrator considered in calculating 

the APQ, but not the AAN, include 

product development requirements of 

both bulk and finished dosage form 

manufacturers. 

After considering the changes in the 

extent of diversion of all controlled 

substances, as required by 21 CFR 

1303.13(b)(1), DEA has determined that 

any changes from the initial calculations 

are slight and not statistically significant 

from the estimates of diversion that DEA 

applied to the initial APQ valuations. 

DEA determined whether to propose 

an adjustment of the AAN for 2023 by 

considering the factors found at 21 CFR 

1315.13(b) and summarized below: 

(1) Changes in the demand for that 

chemical, changes in the national rate of net 

disposal of the chemical, and changes in the 

rate of net disposal of the chemical by 

registrants holding individual manufacturing 

or import quotas for that chemical; 

(2) Whether any increased demand for that 

chemical, the national and/or changes in 

individual rates of net disposal of that 

chemical are temporary, short term, or long 

term; 

(3) Whether any increased demand for that 

chemical can be met through existing 

inventories, increased individual 

manufacturing quotas, or increased 

importation, without increasing the 

assessment of annual needs, taking into 

account production delays and the 

probability that other individual 

manufacturing quotas may be suspended 

pursuant to Sec. 1315.24(b); 

(4) Whether any decreased demand for that 

chemical will result in excessive inventory 

accumulation by all persons registered to 

handle that chemical (including 

manufacturers, distributors, importers, and 

exporters), notwithstanding the possibility 

that individual manufacturing quotas may be 

suspended pursuant to Sec. 1315.24(b) or 

abandoned pursuant to Sec. 1315.27; 

(5) Other factors affecting medical, 

scientific, research, industrial, and 

importation needs in the United States, 

lawful export requirements, and reserve 

stocks, as the Administrator finds relevant, 

including changes in the currently accepted 

medical use in treatment with the chemical 

or the substances that are manufactured from 

it, the economic and physical availability of 

raw materials for use in manufacturing and 

for inventory purposes, yield and stability 

problems, potential disruptions to 

production (including possible labor strikes), 

and recent unforeseen emergencies such as 

floods and fires. 

In evaluating whether there is a need 

for adjustment of the 2023 AAN for list 

I chemicals, DEA used the calculation 

methodology previously described in 

the 2010 and 2011 assessment of annual 

needs.5 DEA considered the total net 

disposals of the list I chemicals for the 

current and preceding two years, actual 

and estimated inventories, projected 

demand, industrial use, and export 

requirements from data provided by 

DEA registered manufacturers and 

importers on the relevant quota 

application forms.6

Additional Considerations Applicable to 

Covered Controlled Substances 

When setting APQ, the Administrator 

must estimate the amount of diversion 

of any substance that is considered a 

‘‘covered controlled substance.’’ 7 The 

covered controlled substances are 

fentanyl, oxycodone, hydrocodone, 

oxymorphone, and hydromorphone.8

DEA is required to ‘‘make appropriate 

quota reductions, as determined by the 

[Administrator], from the quota the 

[Administrator] would have otherwise 

established had such diversion not been 

considered.’’ 9 When estimating 

diversion, the Administrator ‘‘shall 

consider information,’’ in consultation 

with the Secretary of Health and Human 

Services, the Administrator ‘‘determines 

reliable on rates of overdose deaths and 

abuse and overall public health impact 

related to the covered controlled 

substance in the United States;’’ and 

‘‘may take into consideration’’ whatever 

other sources of information they 

determine reliable.10

DEA sent letters to the Centers for 

Disease Control and Prevention (CDC), 

and the states in February, April, and 

May 2023 requesting overdose death 

and overprescribing data that could be 

considered in estimating diversion. DEA 

received information from the CDC in 

April 2023 and received Prescription 

Data Monitoring Program (PDMP) data 

from the states in May and June 2023. 

DEA considered this information in 

developing the estimates of diversion 

for the five covered controlled 

substances for this proposed 

adjustment. 

To determine the estimates of 

diversion, DEA also aggregated data for 

each covered controlled substance from 

the Drug Theft and Loss Reports. DEA 

gathered data involving employee theft, 

break-ins, armed robberies, and material 

lost in transit. DEA calculated the 

metric weight in grams of each active 

pharmaceutical ingredient (API) of the 

controlled substances being diverted as 

identified in these reports. In 

calculating the estimates of diversion, 

DEA utilized the same methodology as 

published in the Proposed APQ for 

Schedule I and II Controlled Substances 

and AAN for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2023.11

Below, DEA provides an updated chart 

showing estimations of diversion for 

each of the covered controlled 

substances. 

DIVERSION ESTIMATES FOR 2023 (g) 

Fentanyl 59 

Hydrocodone .................................. 133,004 

Hydromorphone .............................. 595 

Oxycodone ...................................... 174,797 

Oxymorphone ................................. 109 

Proposed Adjustments for the 2023 

Aggregate Production Quotas and 

Assessment of Annual Needs 

DEA is proposing increases to the 

APQ for the following schedule I 

substances: all other 

tetrahydrocannabinol, delta-9- 

tetrahydrocannabinol, ibogaine, 

psilocybin, and psilocyn. These 

proposed increases are to support 

research and clinical trials by DEAregistered schedule I researchers. These 

proposed increases demonstrate DEA’s 

support for research with schedule I 

controlled substances. 

DEA established the 2023 APQs for 

substances in schedules I and II on 

December 2, 2022.12 Subsequent to that 

publication, DEA published in the 

Federal Register final rules to 

permanently schedule four synthetic 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 74515 

13 87 FR 70717 (November 21, 2022), 87 FR 71247 

(November 22, 2022), 87 FR 20318 (April, 7 2022), 

and 87 FR 32996 (June 1, 2022). 

14Adjustment to the Aggregate Production Quota 

for Methylphenidate (for Sale) for 2023, 88 FR 

68147 (October 3, 2023). 

drugs under the CSA.13 The specific 

synthetic substances are eutylone, 

mesocarb, methiopropamine, and 

zipeprol. As a result, these substances 

will continue to be subject to the CSA 

schedule I controls and DEA is 

proposing to assign individual APQ for 

each substance pursuant to 21 U.S.C. 

826 and 21 CFR part 1303. 

DEA previously adjusted the 

established 2023 aggregate production 

quota for the schedule II-controlled 

substance methylphenidate (for sale) to 

be manufactured in the United States to 

provide for the estimated needs of the 

United States and export requirements 

in accordance with 21 U.S.C. 826(h).14

This adjustment was necessary to 

ensure that the United States has an 

adequate and uninterrupted supply of 

methylphenidate (for sale) to meet 

legitimate patient needs both 

domestically and globally. 

The Administrator, therefore, 

proposes to adjust the 2023 APQ for the 

schedule I controlled substances of all 

other tetrahydrocannabinol, delta-9- 

tetrahydrocannabinol, eutylone, 

ibogaine, mesocarb, methiopropamine, 

psilocybin, psilocyn, and zipeprol. The 

proposed adjusted APQ and AAN, as 

expressed in grams of anhydrous acid or 

base, are as follows: 

Basic class 

Established 

2023 quotas 

(g) 

Proposed revised 

2023 quotas 

(g) 

Schedule I 

1-[1-(2-Thienyl)cyclohexyl]pyrrolidine .......................................................................................................... 20 no change. 

1-(1-Phenylcyclohexyl)pyrrolidine ................................................................................................................ 30 no change. 

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine .......................................................................................... 10 no change. 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) .................................................................................... 30 no change. 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ................................................................................... 30 no change. 

1-[1-(2-Thienyl)cyclohexyl]piperidine ........................................................................................................... 15 no change. 

2′-fluoro 2-fluorofentanyl .............................................................................................................................. 30 no change. 

1-Benzylpiperazine ...................................................................................................................................... 25 no change. 

1-Methyl-4-phenyl-4-propionoxypiperidine ................................................................................................... 10 no change. 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) .................................................................................. 30 no change. 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) ............................................................................... 30 no change. 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) ................................................................................. 30 no change. 

2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P) ............................................................................. 30 no change. 

2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) .............................................................................................. 100 no change. 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; 

Cimbi-36) .................................................................................................................................................. 30 no change. 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) ................................................................................ 30 no change. 

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 

25C; Cimbi-82) ......................................................................................................................................... 25 no change. 

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) ..................................................................................... 30 no change. 

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; 

Cimbi-5) .................................................................................................................................................... 30 no change. 

2,5-Dimethoxy-4-ethylamphetamine (DOET) .............................................................................................. 25 no change. 

2,5-Dimethoxy-4-n-propylthiophenethylamine ............................................................................................. 25 no change. 

2,5-Dimethoxyamphetamine ........................................................................................................................ 25 no change. 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ....................................................................... 30 no change. 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) ................................................................ 30 no change. 

3,4,5-Trimethoxyamphetamine .................................................................................................................... 30 no change. 

3,4-Methylenedioxyamphetamine (MDA) .................................................................................................... 12,000 no change. 

3,4-Methylenedioxymethamphetamine (MDMA) ......................................................................................... 12,000 no change. 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ..................................................................................... 40 no change. 

3,4-Methylenedioxy-N-methylcathinone (methylone) .................................................................................. 5,200 no change. 

3,4-Methylenedioxypyrovalerone (MDPV) ................................................................................................... 35 no change. 

3–FMC; 3-Fluoro-N-methylcathinone .......................................................................................................... 25 no change. 

3-Methylfentanyl ........................................................................................................................................... 30 no change. 

3-Methylthiofentanyl ..................................................................................................................................... 30 no change. 

4-Bromo-2,5-dimethoxyamphetamine (DOB) .............................................................................................. 5,100 no change. 

4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ......................................................................................... 25 no change. 

4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro-alpha-PVP) ................................................................. 25 no change. 

4–CN-Cumyl-Butinaca ................................................................................................................................. 25 no change. 

4,4′-Dimethylaminorex ................................................................................................................................. 30 no change. 

4-Fluoroisobutyryl fentanyl ........................................................................................................................... 30 no change. 

4F–MDMB–BINACA .................................................................................................................................... 30 no change. 

4–FMC; Flephedrone ................................................................................................................................... 25 no change. 

4–MEC; 4-Methyl-N-ethylcathinone ............................................................................................................. 25 no change. 

4-Methoxyamphetamine .............................................................................................................................. 150 no change. 

4-Methyl-2,5-dimethoxyamphetamine (DOM) .............................................................................................. 25 no change. 

4-Methylaminorex ........................................................................................................................................ 25 no change. 

4-Methyl-N-methylcathinone (mephedrone) ................................................................................................ 45 no change. 

4-Methyl-alpha-ethylaminopentiophenone (4–MEAP) ................................................................................. 25 no change.

4-Methyl-alpha-pyrrolidinohexiophenone (MPHP) ....................................................................................... 25 no change. 

4′-Methyl acetyl fentanyl .............................................................................................................................. 30 no change. 


lotter on DSK11XQN23PROD with NOTICES1
74516 Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 

Basic class 

Established 

2023 quotas 

(g) 

Proposed revised 

2023 quotas 

(g) 

4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ....................................................................................... 25 no change. 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ................................................................. 50 no change. 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8- 

homolog) .................................................................................................................................................. 40 no change. 

5F–AB–PINACA; (1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ..... 25 no change. 

5F–ADB; 5F–MDMB–PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3- 

dimethylbutanoate) ................................................................................................................................... 25 no change. 

5F–CUMYL–P7AICA; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine3carboximide ............................................................................................................................................ 25 no change. 

5F–CUMYL–PINACA ................................................................................................................................... 25 no change. 

5F–EDMB–PINACA ..................................................................................................................................... 25 no change. 

5F–MDMB–PICA ......................................................................................................................................... 25 no change. 

5F–AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) .......................... 25 no change. 

5F–APINACA; 5F–AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ............... 25 no change. 

5-Fluoro-PB–22; 5F–PB–22 ........................................................................................................................ 25 no change. 

5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .... 25 no change. 

5-Methoxy-3,4-methylenedioxyamphetamine .............................................................................................. 25 no change. 

5-Methoxy-N,N-diisopropyltryptamine .......................................................................................................... 25 no change. 

5-Methoxy-N,N-dimethyltryptamine ............................................................................................................. 11,000 no change. 

AB–CHMINACA ........................................................................................................................................... 30 no change. 

AB–FUBINACA ............................................................................................................................................ 50 no change. 

AB–PINACA ................................................................................................................................................. 30 no change. 

ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3- 

carboxamide) ............................................................................................................................................ 30 no change. 

Acetorphine .................................................................................................................................................. 25 no change. 

Acetyl Fentanyl ............................................................................................................................................ 100 no change. 

Acetyl-alpha-methylfentanyl ......................................................................................................................... 30 no change. 

Acetyldihydrocodeine ................................................................................................................................... 30 no change. 

Acetylmethadol ............................................................................................................................................ 25 no change. 

Acryl Fentanyl .............................................................................................................................................. 25 no change. 

ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ............. 50 no change. 

AH–7921 ...................................................................................................................................................... 30 no change. 

All other tetrahydrocannabinol ..................................................................................................................... 15,000 350,000. 

Allylprodine .................................................................................................................................................. 25 no change. 

Alphacetylmethadol ...................................................................................................................................... 25 no change. 

alpha-Ethyltryptamine .................................................................................................................................. 25 no change. 

Alphameprodine ........................................................................................................................................... 25 no change. 

Alphamethadol ............................................................................................................................................. 25 no change. 

alpha-Methylfentanyl .................................................................................................................................... 30 no change. 

alpha-Methylthiofentanyl .............................................................................................................................. 30 no change. 

alpha-Methyltryptamine (AMT) .................................................................................................................... 25 no change. 

alpha-Pyrrolidinobutiophenone (a-PBP) ...................................................................................................... 25 no change. 

alpha-pyrrolidinoheptaphenone (PV8) ......................................................................................................... 25 no change. 

alpha-pyrrolidinohexabophenone (a -PHP) ................................................................................................. 25 no change. 

alpha-Pyrrolidinopentiophenone (a-PVP) .................................................................................................... 25 no change. 

Amineptine ................................................................................................................................................... 30 no change. 

Aminorex ...................................................................................................................................................... 25 no change. 

Anileridine .................................................................................................................................................... 20 no change. 

APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ................................................. 25 no change. 

Benzethidine ................................................................................................................................................ 25 no change. 

Benzylmorphine ........................................................................................................................................... 30 no change. 

Betacetylmethadol ....................................................................................................................................... 25 no change. 

beta-Hydroxy-3-methylfentanyl .................................................................................................................... 30 no change. 

beta-Hydroxyfentanyl ................................................................................................................................... 30 no change. 

beta-Hydroxythiofentanyl ............................................................................................................................. 30 no change. 

beta-Methyl fentanyl .................................................................................................................................... 30 no change. 

beta-Phenyl fentanyl .................................................................................................................................... 30 no change. 

Betameprodine ............................................................................................................................................. 25 no change. 

Betamethadol ............................................................................................................................................... 4 no change. 

Betaprodine .................................................................................................................................................. 25 no change. 

Brorphine ..................................................................................................................................................... 30 no change. 

Bufotenine .................................................................................................................................................... 15 no change. 

Butonitazene ................................................................................................................................................ 30 no change. 

Butylone ....................................................................................................................................................... 25 no change. 

Butyryl fentanyl ............................................................................................................................................ 30 no change. 

Cathinone ..................................................................................................................................................... 40 no change. 

Clonitazene .................................................................................................................................................. 25 no change. 

Codeine methylbromide ............................................................................................................................... 30 no change. 

Codeine-N-oxide .......................................................................................................................................... 192 no change. 

Crotonyl Fentanyl ......................................................................................................................................... 25 no change. 

Cyclopentyl Fentanyl ................................................................................................................................... 30 no change. 

Cyclopropyl Fentanyl ................................................................................................................................... 20 no change. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 74517 

Basic class 

Established 

2023 quotas 

(g) 

Proposed revised 

2023 quotas 

(g) 

Cyprenorphine ............................................................................................................................................. 25 no change. 

d-9–THC ...................................................................................................................................................... 384,460 628,460. 

Desomorphine .............................................................................................................................................. 25 no change. 

Dextromoramide .......................................................................................................................................... 25 no change. 

Diapromide ................................................................................................................................................... 20 no change. 

Diethylthiambutene ...................................................................................................................................... 20 no change. 

Diethyltryptamine ......................................................................................................................................... 25 no change. 

Difenoxin ...................................................................................................................................................... 9,300 no change. 

Dihydromorphine .......................................................................................................................................... 653,548 no change. 

Dimenoxadol ................................................................................................................................................ 25 no change. 

Dimepheptanol ............................................................................................................................................. 25 no change. 

Dimethylthiambutene ................................................................................................................................... 20 no change. 

Dimethyltryptamine ...................................................................................................................................... 3,000 no change. 

Dioxyaphetyl butyrate .................................................................................................................................. 25 no change. 

Dipipanone ................................................................................................................................................... 25 no change. 

Drotebanol ................................................................................................................................................... 25 no change. 

Ethylmethylthiambutene ............................................................................................................................... 25 no change. 

Ethylone ....................................................................................................................................................... 25 no change. 

Etonitazene .................................................................................................................................................. 25 no change. 

Etodesnitazene ............................................................................................................................................ 30 no change. 

Etorphine ...................................................................................................................................................... 30 no change. 

Etoxeridine ................................................................................................................................................... 25 no change. 

Eutylone ....................................................................................................................................................... N/A 30. 

Fenethylline .................................................................................................................................................. 30 no change. 

Fentanyl carbamate ..................................................................................................................................... 30 no change. 

Fentanyl related substances ........................................................................................................................ 600 no change. 

FUB–144 ...................................................................................................................................................... 25 no change. 

Flunitazene .................................................................................................................................................. 30 no change. 

FUB–AKB48 ................................................................................................................................................. 25 no change. 

Fub-AMB, MMB-Fubinaca, AMB-Fubinaca ................................................................................................. 25 no change. 

Furanyl fentanyl ........................................................................................................................................... 30 no change. 

Furethidine ................................................................................................................................................... 25 no change. 

gamma-Hydroxybutyric acid ........................................................................................................................ 29,417,000 no change. 

Heroin .......................................................................................................................................................... 150 no change. 

Hydromorphinol ............................................................................................................................................ 40 no change. 

Hydroxypethidine ......................................................................................................................................... 25 no change. 

Ibogaine ....................................................................................................................................................... 30 150. 

Isobutyryl Fentanyl ....................................................................................................................................... 25 no change. 

Isotonitazine ................................................................................................................................................. 25 no change. 

JWH–018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) ............................................................................. 35 no change. 

JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) .................................................................................................. 45 no change. 

JWH–073 (1-Butyl-3-(1-naphthoyl)indole) ................................................................................................... 45 no change. 

JWH–081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) .............................................................................. 30 no change. 

JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .................................................................................. 30 no change. 

JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ...................................................................... 35 no change. 

JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) ................................................................................... 30 no change. 

JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ............................................................................... 30 no change. 

JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) ................................................................................... 30 no change. 

Ketobemidone .............................................................................................................................................. 30 no change. 

Levomoramide ............................................................................................................................................. 25 no change. 

Levophenyacylmorphan ............................................................................................................................... 25 no change. 

Lysergic acid diethylamide (LSD) ................................................................................................................ 1,200 no change. 

MAB–CHMINACA; ADB–CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 

1H-indazole-3-carboxamide) .................................................................................................................... 30 no change. 

MDMB–CHMICA; MMB–CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3- 

dimethylbutanoate) ................................................................................................................................... 30 no change. 

MDMB–FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .. 30 no change. 

MMB–CHMICA-(AMB–CHIMCA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3- 

methylbutanoate ....................................................................................................................................... 25 no change. 

Marijuana ..................................................................................................................................................... 6,675,000 no change. 

Marijuana extract ......................................................................................................................................... 1,000,000 no change. 

Mecloqualone ............................................................................................................................................... 30 no change. 

Mescaline ..................................................................................................................................................... 1,200 no change. 

Mesocarb ..................................................................................................................................................... N/A 30. 

Methaqualone .............................................................................................................................................. 60 no change. 

Methcathinone ............................................................................................................................................. 25 no change. 

Methiopropamine ......................................................................................................................................... N/A 30. 

Methoxetamine ............................................................................................................................................ 30 no change. 

Methoxyacetyl fentanyl ................................................................................................................................ 30 no change. 

Methyldesorphine ......................................................................................................................................... 5 no change. 

Methyldihydromorphine ................................................................................................................................ 25 no change. 

Metodesnitazene .......................................................................................................................................... 30 no change. 


lotter on DSK11XQN23PROD with NOTICES1
74518 Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 

Basic class 

Established 

2023 quotas 

(g) 

Proposed revised 

2023 quotas 

(g) 

Metonitazene ............................................................................................................................................... 30 no change. 

Morpheridine ................................................................................................................................................ 25 no change. 

Morphine methylbromide ............................................................................................................................. 5 no change. 

Morphine methylsulfonate ............................................................................................................................ 5 no change. 

Morphine-N-oxide ........................................................................................................................................ 150 no change. 

MT–45 .......................................................................................................................................................... 30 no change. 

Myrophine .................................................................................................................................................... 25 no change. 

NM2201: Naphthalen-1-yl 1-(5-fluorpentyl)-1H-indole-3-carboxylate .......................................................... 25 no change. 

N,N-Dimethylamphetamine .......................................................................................................................... 25 no change. 

Naphyrone ................................................................................................................................................... 25 no change. 

N-Ethyl-1-phenylcyclohexylamine ................................................................................................................ 25 no change. 

N-Ethyl-3-piperidyl benzilate ........................................................................................................................ 10 no change. 

N-Ethylamphetamine ................................................................................................................................... 24 no change. 

N-Ethylhexedrone ........................................................................................................................................ 25 no change. 

N-Ethylpentylone, ephylone ......................................................................................................................... 30 no change. 

N-Hydroxy-3,4-methylenedioxyamphetamine .............................................................................................. 24 no change. 

Nicocodeine ................................................................................................................................................. 25 no change. 

Nicomorphine ............................................................................................................................................... 25 no change. 

N-methyl-3-piperidyl benzilate ..................................................................................................................... 30 no change. 

Noracymethadol ........................................................................................................................................... 25 no change. 

N-Pyrrolidino Etonitazene ............................................................................................................................ 30 no change. 

Norlevorphanol ............................................................................................................................................. 2,550 no change. 

Normethadone ............................................................................................................................................. 25 no change. 

Normorphine ................................................................................................................................................ 40 no change. 

Norpipanone ................................................................................................................................................ 25 no change. 

Ocfentanil ..................................................................................................................................................... 25 no change. 

ortho-Fluoroacryl fentanyl ............................................................................................................................ 30 no change. 

ortho-Fluorobutyryl fentanyl ......................................................................................................................... 30 no change. 

ortho-Fluorofentanyl,2-Fluorofentanyl .......................................................................................................... 30 no change. 

ortho-Fluoroisobutyryl fentanyl .................................................................................................................... 30 no change. 

ortho-Methyl acetylfentanyl .......................................................................................................................... 30 no change. 

ortho-Methyl methoxyacetyl fentanyl ........................................................................................................... 30 no change. 

Para-Chlorisobutyrl fentanyl ........................................................................................................................ 30 no change. 

Para-flourobutyryl fentanyl ........................................................................................................................... 25 no change. 

Para-fluorofentanyl ....................................................................................................................................... 25 no change. 

Para-Fluoro furanyl fentanyl ........................................................................................................................ 30 no change. 

Para-Methoxybutyrl fentanyl ........................................................................................................................ 30 no change. 

Para-methoxymethamphetamine ................................................................................................................. 30 no change. 

Para-Methylfentanyl ..................................................................................................................................... 30 no change. 

Parahexyl ..................................................................................................................................................... 5 no change. 

PB–22; QUPIC ............................................................................................................................................. 20 no change. 

Pentedrone .................................................................................................................................................. 25 no change. 

Pentylone ..................................................................................................................................................... 25 no change. 

Phenadoxone ............................................................................................................................................... 25 no change. 

Phenampromide ........................................................................................................................................... 25 no change. 

Phenomorphan ............................................................................................................................................ 25 no change. 

Phenoperidine .............................................................................................................................................. 25 no change. 

Phenyl fentanyl ............................................................................................................................................ 30 no change. 

Pholcodine ................................................................................................................................................... 5 no change. 

Piritramide .................................................................................................................................................... 25 no change. 

Proheptazine ................................................................................................................................................ 25 no change. 

Properidine ................................................................................................................................................... 25 no change. 

Propiram ...................................................................................................................................................... 25 no change. 

Protonitazene ............................................................................................................................................... 30 no change. 

Psilocybin ..................................................................................................................................................... 8,000 15,000. 

Psilocyn ........................................................................................................................................................ 12,000 24,000. 

Racemoramide ............................................................................................................................................. 25 no change. 

SR–18 and RCS–8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ................................................. 45 no change. 

SR–19 and RCS–4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) .................................................................... 30 no change. 

Tetrahydrofuranyl fentanyl ........................................................................................................................... 15 no change. 

Thebacon ..................................................................................................................................................... 25 no change. 

Thiafentanil .................................................................................................................................................. 25 no change. 

Thiofentanyl ................................................................................................................................................. 25 no change. 

Thiofuranyl fentanyl ..................................................................................................................................... 30 no change. 

THJ–2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) ............................................. 30 no change. 

Tilidine .......................................................................................................................................................... 25 no change. 

Trimeperidine ............................................................................................................................................... 25 no change. 

UR–144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ............................................. 25 no change. 

U–47700 ...................................................................................................................................................... 30 no change. 

Valeryl fentanyl ............................................................................................................................................ 25 no change. 

Zipeprol ........................................................................................................................................................ N/A 30. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 74519 

Basic class 

Established 

2023 quotas 

(g) 

Proposed revised 

2023 quotas 

(g) 

Schedule II 

1-Phenylcyclohexylamine ............................................................................................................................ 15 no change. 

1-Piperidinocyclohexanecarbonitrile ............................................................................................................ 25 no change. 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ................................................................................................. 937,874 no change. 

Alfentanil ...................................................................................................................................................... 5,000 no change. 

Alphaprodine ................................................................................................................................................ 25 no change. 

Amobarbital .................................................................................................................................................. 20,100 no change. 

Amphetamine (for sale)(split) ...................................................................................................................... N/A no change. 

Bezitramide .................................................................................................................................................. 25 no change. 

Carfentanil .................................................................................................................................................... 20 no change. 

Cocaine ........................................................................................................................................................ 60,492 no change. 

Codeine (for conversion) ............................................................................................................................. 1,085,024 no change. 

Codeine (for sale) ........................................................................................................................................ 21,003,397 no change. 

D-amphetamine (for sale) ............................................................................................................................ 21,200,000 no change. 

D,l-amphetamine .......................................................................................................................................... 21,200,000 no change. 

D-amphetamine (for conversion) ................................................................................................................. 20,000,000 no change. 

Dexmethylphenidate (for sale) ..................................................................................................................... 6,200,000 no change. 

Dexmethylphenidate (for conversion) .......................................................................................................... 4,200,000 no change. 

Dextropropoxyphene .................................................................................................................................... 35 no change. 

Dihydrocodeine ............................................................................................................................................ 132,658 no change. 

Dihydroetorphine .......................................................................................................................................... 25 no change. 

Diphenoxylate (for conversion) .................................................................................................................... 14,100 no change. 

Diphenoxylate (for sale) ............................................................................................................................... 770,800 no change. 

Ecgonine ...................................................................................................................................................... 60,492 no change. 

Ethylmorphine .............................................................................................................................................. 30 no change. 

Etorphine hydrochloride ............................................................................................................................... 32 no change. 

Fentanyl ....................................................................................................................................................... 731,452 no change. 

Glutethimide ................................................................................................................................................. 25 no change. 

Hydrocodone (for conversion) ..................................................................................................................... 1,250 no change. 

Hydrocodone (for sale) ................................................................................................................................ 27,239,822 no change. 

Hydromorphone ........................................................................................................................................... 1,994,125 no change. 

Isomethadone .............................................................................................................................................. 30 no change. 

L-amphetamine ............................................................................................................................................ 30 no change. 

Levo-alphacetylmethadol (LAAM) ................................................................................................................ 25 no change. 

Levomethorphan .......................................................................................................................................... 30 no change. 

Levorphanol ................................................................................................................................................. 23,010 no change. 

Lisdexamfetamine ........................................................................................................................................ 26,500,000 no change. 

Meperidine ................................................................................................................................................... 681,289 no change. 

Meperidine Intermediate-A .......................................................................................................................... 30 no change. 

Meperidine Intermediate-B .......................................................................................................................... 30 no change. 

Meperidine Intermediate-C .......................................................................................................................... 30 no change. 

Metazocine ................................................................................................................................................... 15 no change. 

Methadone (for sale) ................................................................................................................................... 25,619,700 no change. 

Methadone Intermediate .............................................................................................................................. 27,673,600 no change. 

Methamphetamine ....................................................................................................................................... 150 no change. 

d-methamphetamine (for conversion) .......................................................................................................... 485,020 no change. 

d-methamphetamine (for sale) .................................................................................................................... 47,000 no change. 

l-methamphetamine ..................................................................................................................................... 587,229 no change. 

Methylphenidate (for sale) ........................................................................................................................... 53,283,000 no change. 

Methylphenidate (for conversion) ................................................................................................................ 15,300,000 no change. 

Metopon ....................................................................................................................................................... 25 no change. 

Moramide-intermediate ................................................................................................................................ 25 no change. 

Morphine (for conversion) ............................................................................................................................ 2,458,460 no change. 

Morphine (for sale) ...................................................................................................................................... 21,747,625 no change. 

Nabilone ....................................................................................................................................................... 62,000 no change. 

Norfentanyl ................................................................................................................................................... 25 no change. 

Noroxymorphone (for conversion) ............................................................................................................... 22,044,741 no change. 

Noroxymorphone (for sale) .......................................................................................................................... 1,000 no change. 

Oliceridine .................................................................................................................................................... 25,100 no change. 

Opium (powder) ........................................................................................................................................... 250,000 no change. 

Opium (tincture) ........................................................................................................................................... 530,837 no change. 

Oripavine ...................................................................................................................................................... 33,010,750 no change. 

Oxycodone (for conversion) ........................................................................................................................ 437,827 no change. 

Oxycodone (for sale) ................................................................................................................................... 53,840,608 no change. 

Oxymorphone (for conversion) .................................................................................................................... 28,204,371 no change. 

Oxymorphone (for sale) ............................................................................................................................... 516,351 no change. 

Pentobarbital ................................................................................................................................................ 33,843,337 no change. 

Phenazocine ................................................................................................................................................ 25 no change. 

Phencyclidine ............................................................................................................................................... 35 no change. 

Phenmetrazine ............................................................................................................................................. 25 no change. 

Phenylacetone ............................................................................................................................................. 100 no change. 


lotter on DSK11XQN23PROD with NOTICES1
74520 Federal Register / Vol. 88, No. 209 / Tuesday, October 31, 2023 / Notices 

15 21 CFR 1303.13(c) and 1315.13(c). 

1The Government’s RFAA is dated June 30, 2022. 

RFAA, at 6. 

2Based on the Declaration from a DEA Diversion 

Investigator, the Agency finds that the 

Government’s service of the OSC on Registrant was 

adequate. RFAAX F, at 1; see also RFAAX A (Form 

DEA–12 signed by Registrant). Further, based on the 

Government’s assertions in its RFAA, the Agency 

finds that more than thirty days have passed since 

Registrant was served with the OSC and Registrant 

has neither requested a hearing nor submitted a 

corrective action plan and therefore has waived any 

such rights. RFAA, at 2; see also 21 CFR 1301.43 

and 21 U.S.C. 824(c)(2). 

3Under the Administrative Procedure Act, an 

agency ‘‘may take official notice of facts at any stage 

in a proceeding—even in the final decision.’’ 

United States Department of Justice, Attorney 

General’s Manual on the Administrative Procedure 

Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint 

1979). Pursuant to 5 U.S.C. 556(e), ‘‘[w]hen an 

agency decision rests on official notice of a material 

fact not appearing in the evidence in the record, a 

party is entitled, on timely request, to an 

opportunity to show the contrary.’’ Accordingly, 

Registrant may dispute the Agency’s finding by 

filing a properly supported motion for 

reconsideration of findings of fact within fifteen 

calendar days of the date of this Order. Any such 

motion and response shall be filed and served by 

email to the other party and to Office of the 

Administrator, Drug Enforcement Administration at 

dea.addo.attorneys@dea.gov. 

4The New York State Education Department 

Office of the Professions lists the status of 

Registrant’s New York medical license as ‘‘summary 

suspension’’, but notes that because the office does 

not discipline physicians, the status listed might be 

impacted by New York State Department of Health 

action and accordingly provides a link to the New 

York State Department of Health Office of 

Professional Medical Conduct Physician Search. 

New York State Education Department Office of the 

Professions, Verification Search, https://

www.op.nysed.gov/verification-search. 

Basic class 

Established 

2023 quotas 

(g) 

Proposed revised 

2023 quotas 

(g) 

Piminodine ................................................................................................................................................... 25 no change. 

Racemethorphan ......................................................................................................................................... 5 no change. 

Racemorphan .............................................................................................................................................. 5 no change. 

Remifentanil ................................................................................................................................................. 3,000 no change. 

Secobarbital ................................................................................................................................................. 172,100 no change. 

Sufentanil ..................................................................................................................................................... 4,000 no change. 

Tapentadol ................................................................................................................................................... 11,941,416 no change. 

Thebaine ...................................................................................................................................................... 57,137,944 no change. 

List I Chemicals 

Ephedrine (for conversion) .......................................................................................................................... 41,100 no change. 

Ephedrine (for sale) ..................................................................................................................................... 4,136,000 no change. 

Phenylpropanolamine (for conversion) ........................................................................................................ 14,878,320 no change. 

Phenylpropanolamine (for sale) ................................................................................................................... 7,990,000 no change. 

Pseudoephedrine (for conversion) .............................................................................................................. 1,000 no change. 

Pseudoephedrine (for sale) ......................................................................................................................... 174,246,000 no change. 

The Administrator further proposes 

that APQ for all other schedule I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 remain at 

zero. In accordance with 21 CFR 

1303.13 and 21 CFR 1315.13, upon 

consideration of the relevant factors, the 

Administrator may adjust the 2023 APQ 

and AAN as needed. 

Conclusion 

After consideration of any comments 

or objections, or after a hearing, if one 

is held, the Administrator will issue and 

publish in the Federal Register a final 

order establishing any adjustment of the 

2023 APQ for each basic class of 

controlled substances in schedules I and 

II and AAN for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine.15

Signing Authority 

This document of the Drug 

Enforcement Administration was signed 

on October 25, 2023, by Administrator 

Anne Milgram. That document with the 

original signature and date is 

maintained by DEA. For administrative 

purposes only, and in compliance with 

requirements of the Office of the Federal 

Register, the undersigned DEA Federal 

Register Liaison Officer has been 

authorized to sign and submit the 

document in electronic format for 

publication, as an official document of 

DEA. This administrative process in no 

way alters the legal effect of this 

document upon publication in the 

Federal Register. 

Scott Brinks, 

Federal Register Liaison Officer, Drug 

Enforcement Administration. 

[FR Doc. 2023–23931 Filed 10–30–23; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Dmitry Anatolevich Shelchkov, M.D.; 

Decision and Order 

On July 21, 2021, the Drug 

Enforcement Administration 

(hereinafter, DEA or Government) 

issued an Order to Show Cause 

(hereinafter, OSC) to Dmitry 

Anatolevich Shelchkov, M.D. 

(hereinafter, Registrant). Request for 

Final Agency Action (hereinafter, 

RFAA), Appendix (hereinafter, RFAAX) 

H, at 1, 4. The OSC proposed the 

revocation of Registrant’s Certificate of 

Registration No. BS8311502 at the 

registered address of 1396 Myrtle 

Avenue, Brooklyn, New York 11237. Id. 

at 1. The OSC alleged that Registrant’s 

registration should be revoked because 

Registrant is ‘‘without authority to 

handle controlled substances in New 

York, the state in which [he is] 

registered with DEA.’’ Id. at 2 (citing 21 

U.S.C. 824(a)(3)). 

The Agency makes the following 

findings of fact based on the 

uncontroverted evidence submitted by 

the Government in its RFAA,1 which 

was fully received on July 12, 2023.2

Findings of Fact 

On March 2, 2021, the New York State 

Commissioner of Health ordered that 

‘‘effective immediately, [Registrant] 

shall not practice medicine in the State 

of New York.’’ RFAAX B, at 1, 3. On 

October 29, 2021, the New York State 

Board for Professional Medical Conduct 

issued a Determination and Order 

revoking Registrant’s New York medical 

license. RFAAX C, at 3–4, 27. According 

to New York’s online records, of which 

the Agency takes official notice, 

Registrant’s New York medical license 

is revoked.3 New York State Department 

of Health Office of Professional Medical 

Conduct Physician Search, https://

apps.health.ny.gov/pubdoh/ 

professionals/doctors/conduct/factions/ 

Home.action (last visited date of 

signature of this Order).4 Accordingly, 


lotter on DSK11XQN23PROD with NOTICES1